Özet:

In patients with solid organ transplants, the incidence of tuberculosis is higher than in normal population. In these patients, tuberculosis is a major cause of morbidity and mortality. Transplant candidates must be scanned for active or latent tuberculosis. This study aims to identify the prevalence of tuberculosis by using the QuantiFERON TB Gold test in pre-transplant donors and recipients. The study was included in the study of a total of 667 patients applicant to organs transplant departments with pre-diagnosis of solid organ transplant recipients and donors between 01.07.2019-01.08.2019 and studied QuantiFERON TB Gold Test (In-Tube Method, Cellestis Limited, Australia). 227 of these patients are donor candidates, and 440 are recipient candidates. The records through the hospital information management system have been examined and the results have been evaluated retrospectively. Comparison of category variables between groups is done by Ki Quadrat test. The overall QuantiFERON test tuberculosis positive rate in transplant recipients was 20.7%, and in donor recipients 13.2%. The QuantiFERON positive ratio in the recipient candidates was significantly high compared to the recipient candidates (p=0.018). The QuantiFERON positive rate was 19.5 per cent in liver receptors, 21.8 per cent in kidney receptors, 25.0 per cent in heart receptors, and there was no significant difference between them in terms of positive rates (p=0.757). Our study is important because solid organ transplantation from our country is among the first tuberculosis scans in donors and their recipients. Furthermore, the scan of both active and latent tuberculosis increases the importance of our study data. Our study of solid organ transplantation has shown the need to catch both donor and new organ-based tuberculosis and receiver-based latent infection as well. We consider that the data of our study will provide important information, especially in our country, to both researchers and clinics, about the pre-transplant active or latent tuberculosis incident.

Anahtar Kelimeler:

Özet:

Objective: The incidence of tuberculosis in patients undergoing solid organ transplantation is higher than in the normal population. Tuberculosis (TB) is an important cause of morbidity and mortality in these patients. Screening for active or latent TB is required in transplant candidates. The aim of this study was to determine the prevalence of TB in donors and recipient candidates using QuantiFERON TB Gold test (‘QFT-G’) before solid organ transplantation. Methods: The study included 667 patients who were referred to organ transplantation departments with the preliminary diagnosis of solid organ transplant recipient and donor between 01.07.2019-01.08.2019 and who were tested using QuantiFERON ‘QFT-G’ (In-Tube Method, Cellestis Limited, Australia). Of these patients, 227 were donor candidates and 440 were recipient candidates. Records were reviewed using the hospital information management system, and the results were evaluated retrospectively. Comparisons between the groups in terms of categorical variables were made using chi-square test. Results: Overall ‘QFT-G’ TB positivity rate was 20.7% in transplant recipient candidates, and was 13.2% in donor candidates. ‘QFT-G’ positivity rate was higher in recipient candidates than donor candidates (p=0.018). ‘QFT-G’positivity rate among solid organ recipient candidates was 19.5% in liver recipients, 21.8% in kidney recipients, 25.0% in heart recipients, and there was no significant difference in terms of positivity rates (p=0.757). Conclusion: Our study has importance because of being among the first TB screening studies conducted on solid organ transplantation donors and recipients in our country. In addition, the screening of both active and latent TB increases the importance of our study data. Our study demonstrated that solid organ transplantation should also capture both donor and new organ-mediated TB and recipient-induced latent infection. We consider that the data of our study will provide important information about the incidence of active or latent TB before transplantation to both researchers and clinicians in our country.